All Oncology News

Phase 2 data showed atezolizumab plus bevacizumab led to limited responses in patients with metastatic colorectal cancer and an MSI-like gene signature.

MD Anderson and SOPHiA GENETICS announce a partnership focused on data-driven oncology tools for clinical practice.

CPI-008 received orphan drug designation from the FDA and EMA for margin detection of pancreatic cancer during surgery.

The first-in-class, CXCR4hi regulatory T-cell therapy CK0804 received orphan drug designation for patients with myelofibrosis.

Post hoc ARAMIS data showed that darolutamide improved MFS and OS in nmCRPC regardless of prior radical prostatectomy or radiotherapy.

Obinutuzumab plus zanubrutinib, pomalidomide, and venetoclax produced high response rates in high-risk MCL.

Preetesh Jain, MD, MBBS, DM, PhD, discusses data with an acalabrutinib-based regimen in high-risk mantle cell lymphoma from the WINDOW-3 trial.

Mahesh Swaminathan, MB, BS, discusses whether the addition of obinutuzumab after 1 year of acalabrutinib/venetoclax is safe and effective in CLL.

Sac-TMT plus pembrolizumab has earned breakthrough therapy designation in China in frontline EGFR- and ALK-negative PD-L1+ NSCLC.

The EMA is reviewing a Type II variation application to expand teclistamab’s label for use with SC daratumumab in relapsed/refractory myeloma.

Two gene mutations, IDH2 and SRSF2, work together to disrupt RNA editing, changing how blood cells develop in acute myeloid leukemia

Orca-T plus allogeneic CAR T-cell therapy may represent a rational treatment approach in high-risk B-cell malignancies.

Sacituzumab govitecan displayed efficacy in terms of PFS both with/without pembrolizumab in patients with untreated TNBC.

Here is your Q1 2026 preview spotlighting 5 FDA decisions to watch, including upcoming PDUFAs for tabelecleucel, pembrolizumab, and more.

Frontline zanubrutinib regimens achieved objective response rates of 100% with deep remissions in elderly and younger, high-risk patients with MCL.

Andrea Franson, MD, MS, discusses safety data on tovorafenib in relapsed or refractory pediatric low-grade glioma from the FIREFLY-1 trial.

The FDA has received a new drug application seeking the approval of rusfertide for the treatment of adult patients with polycythemia vera.

In a phase 1b/2 study, copanlisib plus rucaparib was well tolerated and showed antitumor activity at the RP2D in mCRPC.

Obe-cel produced responses and low rates of high-grade CRS and ICANS in pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Tafasitamab/lenalidomide added to first-line R-CHOP improved PFS vs R-CHOP alone with no new safety signals in patients with DLBCL.

Cardiac surgery and airway reconstruction successfully treated rare cancer that spread to a patient's heart according to researchers at Mayo Clinic.

Cassie Kline, MD, MAS, discusses data from the phase 2 FIREFLY-1 trial of tovorafenib in relapsed/refractory pediatric low-grade glioma.

Embracing the consistency of change allowed Michael Andreeff, MD, PhD, to earn his title as a 2025 Giants of Cancer Care inductee in Translational Science.

The top 5 OncLive TV videos of the week cover insights in leukemia, lung cancer, multiple myeloma, indolent systemic mastocytosis, and pancreatic cancer.

Jason Mouabbi, MD, discusses the emerging role of ctDNA tests in breast cancer management and their use in early detection and treatment monitoring.

With her collaborative ethos and patient-first focus, Lisa A. Carey, MD, ScM, FASCO, is driving innovation in breast cancer research and management.

The FDA cleared narsoplimab for TA-TMA, an NDA seeking approval of bezuclastinib in nonadvanced systemic mastocytosis has been submitted, and more.

Maurie Markman, MD, discusses the essential yet often complex role associated with interpreting numbers and measurements in oncology.

China’s NMPA approved ipilimumab N01 plus sintilimab as neoadjuvant therapy for stage IIB to III resectable MSI-H/dMMR colon cancer.

The FDA has received a new drug application seeking the approval of bezuclastinib for the treatment of patients with non-advanced systemic mastocytosis.